PATENT CLAIM ANALYSIS

Application Number: 16240222
Application Type: Utility
Filing Date: 2019-01
Publication Date: 2019-04
Patent Classification: ["424", "204100"]

Abstract:
The invention relates to vaccine compositions including CEV serogroup immunogens, attenuated and inactivated viruses of the CEV serogroup and chimeric Bunyaviridae. Also disclosed are methods of treating or preventing CEV serogroup infection in a mammalian host, methods of producing a subunit vaccine composition or an immunogenic composition, isolated polynucleotides comprising a nucleotide sequence encoding a CEV serogroup immunogen, methods for detecting La Crosse virus (LACV) infection in a biological sample and infectious chimeric Bunyaviridae.

Claim (Index 5):
A method of inducing an immune response against a La Crosse virus infection in a mammal, comprising administering to the mammal a therapeutically effective dose of an immunogenic composition comprising an infectious chimeric virus comprising a Bunyaviridae genome, wherein one or both of the G C  and G N  genes of the Bunyaviridae genome is substituted with one or both of the counterpart G C  and G N  genes from a La Crosse virus genome, wherein the La Crosse virus genome encodes a G N  glycoprotein having a mutation at amino acid 148.

Metadata:
- Claim Count in Document: 20.0
- Percentile: 99.0
- Lexical Diversity: 1.49091
- Patent Class: 424.0
- Transitional Phrase Type: open
- Component Type: 1
- Foreign Priority: False
- Related Applications: ['12593818', '13633633', '15850696', '10302547', '10371099']

Analysis Scores:
- 35 USC 101 Eligibility (BERT): 0.7548635830773349
- 35 USC 102 Novelty (BERT): 0.6927173894731843
- Combined Prediction Score: 0.7486489637169199
- Mean Citation Score: 564.2183759999998
- Max Citation Score: 788.1304
- Similarity Product: 681.6705600080968

Labels:
- Claim Label 101: 1
- Claim Label 102: 1
- Claim Label 103: 1
- Claim Label 112: 1
- Combined Label: 1
- Label 101 Adjusted: 1

Dataset: test